Early Cancer Diagnostics Powered by Next-Generation Antigen and AI Technology…
Advancing Earlier Cancer Detection. Accelerating Better Outcomes.
OncoFirm™ is a biotechnology company developing innovative antigen-based diagnostic technologies designed to advance the early detection of cancer. Our proprietary fluorescent lateral flow platform combines rapid testing, sensitive biomarker detection, and digital analysis to support the future of accessible, point-of-care cancer diagnostics.
We are building solutions that aim to help clinicians identify cancer-associated biomarkers earlier, enabling faster clinical decision-making and supporting improved patient care.
Innovating the future of early cancer diagnostics—one test at a time.
[Explore Our Technology] [Partner With Us]
Why Early Detection Matters
Earlier diagnosis can improve treatment planning and may contribute to better patient outcomes. Expanding access to rapid, high-quality diagnostic technologies has the potential to reduce delays between testing and clinical evaluation.
OncoFirm is committed to developing technologies that support healthcare providers with timely diagnostic information while advancing innovation in oncology diagnostics.
Built for the Future of Point-of-Care Diagnostics
Our vision extends beyond individual diagnostic tests.
We are developing an integrated diagnostic ecosystem that combines:
- Proprietary antigen technologies
- Fluorescent lateral flow assays
- AI-assisted digital readers
- Cloud-enabled data management
- Future multiplex testing capabilities
This platform approach is intended to support healthcare systems, researchers, distributors, and diagnostic partners worldwide.
Scientific Innovation with Commercial Potential
OncoFirm is advancing its technology through research, product development, strategic collaborations, and commercialization initiatives.
We welcome opportunities to collaborate with:
- Healthcare organizations
- Diagnostic laboratories
- Research institutions
- Distribution partners
- Strategic investors
- Biotechnology companies
Together, we aim to accelerate the future of accessible cancer diagnostics.
OncoFirm™ Diagnostics Rapid Point-of-Care Cancer Diagnostics Using Proprietary Fluorescent Lateral Flow Technology…
Cancer remains one of the leading causes of death worldwide, and outcomes improve significantly when disease is detected early. Many existing diagnostic methods require centralized laboratories, specialized equipment, extended turnaround times, or invasive procedures.
OncoFirm is developing a platform intended to make cancer biomarker testing faster, more accessible, and easier to deploy across a range of healthcare settings.
Our technology is designed to support:
- Early cancer biomarker detection
- Point-of-care diagnostic testing
- Rapid clinical decision support
- Scalable diagnostic manufacturing
- Digital interpretation through AI-enabled analysis
Proprietary Fluorescent Lateral Flow Technology
At the core of our platform is a proprietary fluorescent lateral flow immunoassay engineered to detect targeted cancer-associated antigens with enhanced analytical performance.
Our technology platform is being developed to offer:
- High-sensitivity fluorescent detection
- Multiplex biomarker capabilities
- Rapid results
- Portable diagnostic workflows
- Digital result interpretation
- Scalable manufacturing potential
By combining advanced immunochemistry with digital diagnostics, OncoFirm is working to expand access to earlier cancer detection technologies.
Join Us in Transforming Early Cancer Diagnostics
Whether you are a healthcare provider, researcher, investor, or strategic partner, we invite you to explore how OncoFirm is advancing the next generation of cancer diagnostics through innovative antigen technology.
Together, we can help shape the future of earlier cancer detection.
[Contact Us] [Become a Partner] [Learn About Our Technology]
